Biotech

All Articles

Kezar loses sound lump however to prove its own worth in phase 1 test

.Kezar Lifestyle Sciences is actually dropping its unpromising stage 1 solid cyst medicine as the bi...

Acelyrin loses izokibep, lets go 3rd of team

.In spite of izokibep keeping its own newfound winning touch in the medical clinic, Acelyrin is no l...

Rivus' phase 2 obesity-related heart failure test strikes endpoint

.Rivus Pharmaceuticals has plumped up the prospects of its own fat-busting, muscle-sparing medicine ...

Ovid halts preclinical job, IV program after soticlestat neglect

.Ovid Therapeutics actually uncovered last month that it was trimming its own head count as the prov...

Eli Lilly opens up $700M nucleic acid R&ampD center in Boston Port

.Eli Lilly has actually opened a $700 thousand R&ampD facility in the Boston Port, boosting its own ...

Boundless Biography produces 'modest' discharges five months after $100M IPO

.Simply five months after safeguarding a $100 thousand IPO, Limitless Bio is actually already laying...

Halda's $126M will progress 'hold as well as eliminate' cyst medications

.The preliminary phases of oncology R&ampD aren't short of appealing new methods, and Halda Therapeu...

Lykos 'regrets' certainly not disclosing research study transgressions along with author

.Psychopharmacology has actually drawn 3 articles regarding midstage medical trial information deter...

Analysts examine Avidity's DMD gain, exposing nuances in information

.Avidity Biosciences impressed real estate investors along with period 1/2 data in Duchenne muscle d...

Actinogen's cortisol blocker falls short period 2 clinical depression research

.Actinogen Medical's cortisol blocker has overlooked the key endpoint of a phase 2 research study in...